Supreme Court rejects Novartis' request for stay in Gilenya patent battle
After taking its Gilenya patent battle all the way to the Supreme Court last month, Novartis suffered yet another loss on Thursday — but it isn’t done fighting yet.
The Supreme Court has denied Novartis’ request to stay a lower court’s mandate invalidating a key Gilenya patent. The Swiss pharma giant says it stands to lose more than a quarter billion dollars in sales this year if generics for the blockbuster multiple sclerosis treatment are allowed to market.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.